Early conversion to a CNI-free immunosuppression with SRL after renal transplantation-Long-term follow-up of a multicenter trial.

Joachim AndrassyMarkus GubaAntje HabichtMichael FischerederJohann PratschkeAndreas PascherKatharina M HellerBernhard BanasOliver HakenbergThomas VogelBruno MeiserAndrea DickJens WernerTeresa Kaukenull null

Published in: PloS one (2020)

An early conversion to SRL did not result in an increased incidence of dnDSA nor increased long-term risk for the recipient. Transplant function remains improved with benefits for the graft survival.

Keyphrases

study protocol
risk factors
phase iii
clinical trial
phase ii
cross sectional
free survival
randomized controlled trial